Glaukos (NYSE:GKOS) Sets New 52-Week High on Better-Than-Expected Earnings

Glaukos Corporation (NYSE:GKOS) reached a new 52-week high during trading on Thursday following a better than expected earnings announcement. The company traded as high as $166.00 and last traded at $161.9730, with a volume of 3136767 shares trading hands. The stock had previously closed at $151.33.

The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. The company had revenue of $185.61 million during the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.33%. The company’s revenue for the quarter was up 49.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.24) EPS.

Key Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Glaukos reported record second-quarter revenue of $185.6 million, up approximately 50% year over year and well above the roughly $151 million analyst consensus. The company’s quarterly loss narrowed to $0.14 per share from $0.24 a year earlier, beating expectations. Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up
• Positive Sentiment: Growth was led by the iDose TR sustained-release glaucoma treatment and Epioxa, supporting stronger sales momentum and improved gross profit. Management now expects 2026 net sales of $680 million to $700 million, well above the approximately $630 million consensus forecast. iDose TR sales are projected at $275 million to $280 million. Glaukos outlines 2026 net sales outlook
• Positive Sentiment: BTIG Research raised its price target from $164 to $193 and maintained a Buy rating, indicating continued confidence in Glaukos’s commercial growth potential. BTIG raises Glaukos price target
• Neutral Sentiment: UBS initiated coverage with a Neutral rating and a $150 price target, suggesting the strong outlook is partly reflected in the valuation. Glaukos remains unprofitable, with a negative net margin, while operating cash flow was negative during the quarter.
• Negative Sentiment: Insider-trading data showed continued selling, including a $1.6 million CFO transaction conducted under a pre-arranged Rule 10b5-1 plan. While not necessarily a signal of deteriorating fundamentals, the sales may temper investor sentiment after the stock’s substantial run-up.

Analyst Ratings Changes

Several research analysts have recently commented on GKOS shares. Citigroup increased their price target on shares of Glaukos from $175.00 to $188.00 and gave the stock a “buy” rating in a research note on Thursday. William Blair reiterated an “outperform” rating on shares of Glaukos in a report on Tuesday, May 26th. Wall Street Zen downgraded shares of Glaukos from a “buy” rating to a “hold” rating in a research report on Saturday, July 18th. Stifel Nicolaus raised their target price on Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a report on Thursday. Finally, JPMorgan Chase & Co. boosted their price target on Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Twelve research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $177.33.

Insider Buying and Selling at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 10,000 shares of the business’s stock in a transaction on Thursday, July 16th. The shares were sold at an average price of $160.00, for a total transaction of $1,600,000.00. Following the completion of the transaction, the chief financial officer owned 43,906 shares of the company’s stock, valued at $7,024,960. The trade was a 18.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gilbert H. Kliman sold 5,000 shares of the company’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $140.76, for a total transaction of $703,800.00. Following the sale, the director owned 35,528 shares of the company’s stock, valued at $5,000,921.28. This trade represents a 12.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 40,000 shares of company stock valued at $6,028,800. 5.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Glaukos

A number of institutional investors have recently made changes to their positions in the business. Wealth Alliance LLC increased its stake in shares of Glaukos by 4.5% in the first quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier’s stock valued at $247,000 after buying an additional 98 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in Glaukos by 9.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier’s stock worth $158,000 after buying an additional 122 shares in the last quarter. Larson Financial Group LLC grew its holdings in Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after acquiring an additional 132 shares during the last quarter. CWM LLC grew its holdings in Glaukos by 25.2% during the 4th quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock worth $80,000 after acquiring an additional 143 shares during the last quarter. Finally, Commonwealth Equity Services LLC increased its position in Glaukos by 1.7% in the 4th quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier’s stock valued at $947,000 after acquiring an additional 144 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

Glaukos Stock Up 3.4%

The stock has a market cap of $9.81 billion, a price-to-earnings ratio of -51.42 and a beta of 0.75. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.43. The firm’s 50-day simple moving average is $137.20 and its two-hundred day simple moving average is $124.78.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.